专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0039103B1 DIHYDRO-BENZO(1,4)OXAZINES AND TETRAHYDROQUINOXALINES 审中-公开
标题翻译：二氢苯并（1,4）氧化合物和四氢喹啉酮
公开(公告)号：WO0039103B1
公开(公告)日：2000-09-28
申请号：PCT/GB9904430
申请日：1999-12-23
申请人： AVENTIS PHARMA LTD , BOURZAT JEAN DOMINIQUE , COMMERCON ALAIN , FILOCHE BRUNO JACQUES CHRISTOP , HARRIS NEIL VICTOR , PALLIN THOMAS DAVID , STUTTLE KEITH ALFRED JAMES
发明人： BOURZAT JEAN-DOMINIQUE , COMMERCON ALAIN , FILOCHE BRUNO JACQUES CHRISTOP , HARRIS NEIL VICTOR , PALLIN THOMAS DAVID , STUTTLE KEITH ALFRED JAMES
IPC分类号： A61P11/06 , A61P29/02 , C07D241/38 , C07D265/36 , A61K31/495 , A61K31/535
CPC分类号： C07D241/38 , C07D265/36
摘要： The invention is directed to physiologically active compounds of formula (I) wherein R represents R -Z , R -L -R -Z -, R -L -Ar -L -Z - or R -L -Ar -L -R -Z -; R represents hydrogen, halogen, lower alkyl or lower alkoxy; A represents a straight chain C2-3alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by -ZR , -NY Y , -CO2R or -C(=O)-NY Y ; L represents a direct bond; an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, -S(O)mR , R , -C(=O)-R , -C(=O)-OR , -N(R )-C(=O)-R , -N(R )-C(=O)-OR , -N(R )-SO2-R , -NY Y or -[C(=O)-N(R )-C(R )(R )]p-C(=O)-NY Y , or by (b) alkyl substituted by an acidic functional group, or by S(O)mR , -C(=O)-NY Y or -NY Y ; a -[C(=O)-N(R )-C(R )(R )]p-linkage; a-Z -R -linkage; a -C(=O)-CH2-C(=O)-linkage; a -R -Z -R - linkage; a -C(R )(R )-[C(=O)-N(R )-C(R )(R )]p- linkage; or a -L -L -L - linkage; Z is NR or O; Y is carboxy or an acid bioisostere; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 ( alpha 4 beta 1).
摘要翻译：本发明涉及式（I）的生理活性化合物，其中R 1表示R 3 -Z 3，R 3 -L 2 -R 4 -Z 3 - ， R 3 -L 3 -Ar 1 -L 4 -Z 3 - 或R 3 -L 3 -Ar 1 -L 2 -R 4 -Z <3> - ; R 2表示氢，卤素，低级烷基或低级烷氧基; A 1表示任选被一个或多个选自烷基，芳基，芳基烷基，杂芳基，杂芳基烷基，亚氨基，氧代，硫代基或被-ZR 6，-NY取代的烷基的基团取代的直链C 2-3亚烷基键。 1→Y 2，-CO 2 R 6或-C（= O）-NY 1 Y 2; L 1表示直接键; 亚烷基，亚炔基，亚环烯基，亚环烷基，杂芳基二基，杂环亚烷基或亚芳基，各自任选被（a）酸性官能团，氰基，氧代，-S（O）m R 9，R 3，-C （= O）-R 3，-C（= O）-OR 3，-N（R 8）-C（= O）-R 9，-N（R 8） -C（= O）-OR 9，-N（R 8）-SO 2 -R 9，-NY 4 Y 5或 - [C（= O） 10））-C（R 5）（R 11）] pC（= O）-NY 4 Y 5或（b）被酸官能团取代的烷基，或被S（ O）m R 9，-C（= O）-NY 4 Y 5或-NY 4 Y 5; a - [C（= O）-N（R 10）-C（R 5）（R 11）] p - 键; A-Z <2> -R <12> - 键; -C（= O）-CH 2 -C（= O） - 链接; -R 12 -Z 2 -R 12 - 键; -C（R 4）（R 13） - [C（= O）-N（R 10）-C（R 5）（R 11）] p键; 或-L 5 -L 6 -L 7 - 键; Z 1是NR 17或O; Y是羧基或酸生物电子等排体; 和相应的N-氧化物及其前药; 和这些化合物及其N-氧化物和前药的药学上可接受的盐和溶剂化物。这些化合物具有有价值的药物性质，特别是调节VCAM-1和纤连蛋白与整联蛋白VLA-4（α4β1）的相互作用的能力。

2. 发明申请

WO1997003967A1 SUBSTITUTED AROMATIC COMPOUNDS AND THEIR PHARMACEUTICAL USE 审中-公开
标题翻译：取代芳香化合物及其药物用途
公开(公告)号：WO1997003967A1
公开(公告)日：1997-02-06
申请号：PCT/GB1996001746
申请日：1996-07-22
申请人： RHONE-POULENC RORER LIMITED , ALDOUS, David, John , SMITH, Graham, Frank , ASTLES, Peter, Charles , PICKETT, Stephen, Dennis , McLAY, Iain, McFarlane , STUTTLE, Keith, Alfred, James , RATCLIFFE, Andrew, James
发明人： RHONE-POULENC RORER LIMITED
IPC分类号： C07D213/81
CPC分类号： C07D213/75 , C07D213/61 , C07D213/81 , C07D213/89 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The invention describes compounds of formula (I), wherein R is optionally substituted alkyl, or when Z is a direct bond R may also represent hydrogen; R is optionally substituted aryl, partially saturated bicycloaryl, heteroaryl or R R N-; R is optionally substituted aryl or heteroaryl group; A is a bond, optionally substituted C1-6alkylene, or C2-6alkylene containing a double or triple bond, or interrupted by oxygen, sulphur, phenylene, imino, alkylimino, sulphinyl or sulphonyl; Z is oxygen, sulphur or a bond; Z is oxygen, sulphur or a bond; Z is -CC-, -CH2-CZ-, -CZ-CH2-, -CZ-CZ-, -CH2-NH-, -CH2-O-, -CH2-S-, -CH2-SO-, -CH2-SO2-, -CF2-O-, -CZ-NH-, -NH-CH2-, -O-CH2-, -S-CH2-, -SO-CH2-, -SO2-CH2-, -O-CF2-, -O-CZ-, -NH-CZ-, -N=N-, -NH-SO2-, -SO2-NH-, -CZ-CZ-NH-, -NH-CO-O-, -O-CO-NH-, -C(=NOR )CH2-, -C(F)=N-, -CH(F)-CH2-, or -NH-CO-NH-; Z is oxygen or sulphur; R and R each independently are alkyl or arylalkyl, or NR R forms a 4-6 membered cyclic amine which optionally contains an additional heteroatom selected from O, S, NH or NR , or is substituted with an oxo group; R is alkyl or arylalkyl; Q , Q and Q are each CH or CX or N; and X is halogen; and N-oxides thereof, and their prodrugs, pharmaceutically acceptable salts, and solvates (e.g. hydrates), thereof. The invention also describes processes for preparing the compounds of formula (I), pharmaceutical compositions comprising such compounds and their use in therapy as inhibitors of TNF and type IV cyclic AMP phosphodiesterase (PDE).
摘要翻译：本发明描述了式（I）的化合物，其中R 1是任选取代的烷基，或当Z 1是直接键时，R 1也可以表示氢; R 2是任选取代的芳基，部分饱和的双环芳基，杂芳基或R a R N; R 3是任选取代的芳基或杂芳基; A 1是一个键，任意取代的C 1-6亚烷基，或含有双键或三键的C2-6亚烷基，或被氧，硫，亚苯基，亚氨基，烷基亚氨基，亚磺酰基或磺酰基间隔的键; Z 1是氧，硫或键; Z 2是氧，硫或键; Z 3是-C≡C，-CH 2 -CZ-，-CZ-CH 2 - ， - CZ-CZ - ， - CH 2 -NH-，-CH 2 -O - ， - CH 2 -S-， - CH 2 -SO- ，-CH 2 -SO 2 - ，-CF 2 -O-，-CZ-NH-，-NH-CH 2 - ， - O-CH 2 - ， - S-CH 2 - ， - SO-CH 2 - ， - SO 2 -CH 2 - O-CF 2 - ，-O-CZ - ， - NH-CZ - ， - N = N-，-NH-SO 2 - ， - SO 2 -NH-，-CZ-CZ-NH-，-NH-CO- ，-O-CO-NH-，-C（= NOR c）CH 2 - ， - C（F）= N-，-CH（F）-CH 2 - 或-NH-CO-NH-; Z是氧或硫; R a和R b各自独立地是烷基或芳烷基，或NR a R b形成4-6元环胺，其任选地含有选自O，S，NH或NR c的另外的杂原子或被氧代基团取代; R c是烷基或芳基烷基; Q 1，Q 2和Q 3各自为CH或CX 1或N; X 1为卤素; 及其N-氧化物及其前药，药学上可接受的盐和溶剂化物（例如水合物）。本发明还描述了制备式（I）化合物的方法，包含这些化合物的药物组合物及其在作为TNF和IV型环AMP磷酸二酯酶（PDE）抑制剂的治疗中的用途。

3. 发明申请

WO2004067524A1 EP4 RECEPTOR ANTAGONISTS 审中-公开
标题翻译： EP4受体拮抗剂
公开(公告)号：WO2004067524A1
公开(公告)日：2004-08-12
申请号：PCT/GB2004/000347
申请日：2004-01-29
申请人： PHARMAGENE LABORATORIES LIMITED , CLARK, David, Edward , CLARK, Kenneth, Lyle , COLEMAN, Robert, Alexander , DAVIS, Richard, Jon , FENTON, Garry , HARRIS, Neil, Victor , HYND, George , NEWTON, Christoper, Gregory , OXFORD, Alexander, William , STUTTLE, Keith, Alfred, James , SUTTON, Jonathan, Mark
发明人： CLARK, David, Edward , CLARK, Kenneth, Lyle , COLEMAN, Robert, Alexander , DAVIS, Richard, Jon , FENTON, Garry , HARRIS, Neil, Victor , HYND, George , NEWTON, Christoper, Gregory , OXFORD, Alexander, William , STUTTLE, Keith, Alfred, James , SUTTON, Jonathan, Mark
IPC分类号： C07D307/52
CPC分类号： C07D405/12 , C07D307/54 , C07D307/68 , C07D407/12 , C07D409/12 , C07D411/12 , C07D413/12
摘要： Compounds of formula (I): wherein: R 2 is H or an optionally substituted C 1-4 alkyl group; Y is either -(CH 2 ) n -X-, where n is 1 or 2 and X is O, S, S(=O), S(=O) 2 , or NR N1 , where R N 1 is selected from H or optionally substituted C 1-4 alkyl, or Y is -C(=O)NR N2 -, where R N2 is selected from H, and optionally substituted C 1-7 alkyl or C 5-20 aryl; R 3 is an optionally substituted C 6 aryl group linked to a further optionally substituted C 6 aryl group, wherein if both C 6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C 1-3 alkylene group; and R 5 is either:(i) carboxy;(ii) a group of formula (II); or(iii) a group of formula (III):, wherein R is optionally substituted C 1-7 alkyl, C 5-20 aryl or NR N3 R N4 , where R N3 and R N4 are independently selected from optionally substituted C 1-4 alkyl;(iv) tetrazol-5-yl.
摘要翻译：式（I）的化合物：其中：R 2是H或任选取代的C 1-4烷基; Y为 - （CH2）nX-，其中n为1或2，X为O，S，S（= O），S（= O）2或NR

4. 发明申请

WO1994002465A1 INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF 审中-公开
标题翻译： c-AMP磷酸二酯酶和TNF的抑制剂
公开(公告)号：WO1994002465A1
公开(公告)日：1994-02-03
申请号：PCT/GB1993001597
申请日：1993-07-28
申请人： RHONE-POULENC RORER LIMITED , FENTON, Garry , MORLEY, Andrew, David , PALFREYMAN, Malcolm, Norman , RATCLIFFE, Andrew, James , SHARP, Brian, William , STUTTLE, Keith, Alfred, James , THURAIRATNAM, Sukanthini , VACHER, Bernard, Yvon, Jack
发明人： RHONE-POULENC RORER LIMITED
IPC分类号： C07D213/75
CPC分类号： C07D213/75 , C07C43/225 , C07C45/004 , C07C45/292 , C07C45/71 , C07C47/575 , C07C49/84 , C07C59/58 , C07C59/60 , C07C59/62 , C07C65/21 , C07C65/24 , C07C65/42 , C07C69/76 , C07C69/92 , C07C205/59 , C07C217/88 , C07C235/56 , C07C255/60 , C07C275/34 , C07C311/29 , C07C311/46 , C07C317/40 , C07C323/42 , C07C327/48 , C07C2601/08 , C07C2601/14 , C07C2602/42 , C07D213/50 , C07D213/89 , C07D239/42 , C07D241/20 , C07D261/14 , C07D275/03 , C07D409/12
摘要： This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
摘要翻译：本发明涉及通过各种连接与芳基部分连接的用于抑制肿瘤坏死因子的苯基化合物的药物用途。本发明还涉及含有这些化合物的化合物及其制备方法和药物组合物。此外，本发明涉及化合物抑制环AMP磷酸二酯酶的药物用途。

5. 发明申请

WO1992017470A1 IMIDAZOLES 审中-公开
标题翻译：的咪唑
公开(公告)号：WO1992017470A1
公开(公告)日：1992-10-15
申请号：PCT/GB1992000560
申请日：1992-03-27
申请人： RHONE-POULENC RORER LIMITED , HARRIS, Neil, Victor , SMITH, Christopher , STUTTLE, Keith, Alfred, James , WALSH, Roger, John, Aitchison , WYMAN, Barry, Mark
发明人： RHONE-POULENC RORER LIMITED
IPC分类号： C07D405/04
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D405/04 , C07D405/14
摘要： Imidazole derivatives of formula (I), wherein R1 represents optionally substituted phenyl, R2 represents alkyl optionally substituted by hydroxy, X1 represents a bond, oxygen, -S(O)¿n?-, -CH2O- or - CH2N(R?6¿)-, wherein n is 0, 1 or 2 and R6 represents hydrogen, alkyl, acyl alkylsulphonyl or, -C(X3)NR7R8, wherein X3 represents oxygen or sulphur and R?7 and R8¿ represent hydrogen, alkyl, or optionally substituted phenyl, m is zero or 1 to 8, X2 represents a bond, oxygen, -S(O)¿p?-wherein p is 0, 1 or 2, or a group -C(O)NR?4¿-, -C(S)NR4-, -OC(O)NR4-, -OC(S)NR?4-, -NR4¿C(O)- or -NR4C(S)-, wherein R4 represents hydrogen or alkyl and R3 represents optionally substituted heterocyclyl, or cycloalkyl or, except when X?1 and X2¿ are direct bonds, R3 represents optionally substituted phenyl, or R3 represents amino, alkylamino, benzylamino, benzyl(alkyl)amino, dialkylamino, aminoalkyl, alkylaminoalkyl, benzylaminoalkyl, benzyl(alkyl)aminoalkyl or dialkylaminoalkyl, or a cyclic imino group, and salts thereof possess useful pharmacological properties.

6. 发明申请

WO2007017687A2 EP2 RECEPTOR AGONISTS 审中-公开
标题翻译： EP2受体激素
公开(公告)号：WO2007017687A2
公开(公告)日：2007-02-15
申请号：PCT/GB2006/002979
申请日：2006-08-09
申请人： ASTERAND UK LIMITED , OXFORD, Alexander, William , DAVIS, Richard, Jon , COLEMAN, Robert, Alexander , CLARK, Kenneth, Lyle , CLARK, David, Edward , HARRIS, Neil, Victor , FENTON, Garry , HYND, George , STUTTLE, Keith, Alfred, James , SUTTON, Jonathan, Mark , ASHTON, Mark, Richard , BOYD, Edward, Andrew , BRUNTON, Shirley, Ann
发明人： OXFORD, Alexander, William , DAVIS, Richard, Jon , COLEMAN, Robert, Alexander , CLARK, Kenneth, Lyle , CLARK, David, Edward , HARRIS, Neil, Victor , FENTON, Garry , HYND, George , STUTTLE, Keith, Alfred, James , SUTTON, Jonathan, Mark , ASHTON, Mark, Richard , BOYD, Edward, Andrew , BRUNTON, Shirley, Ann
CPC分类号： C07C233/81 , C07C257/18 , C07D213/70 , C07D263/57 , C07D307/42 , C07D307/54 , C07D307/68 , C07D307/91 , C07D405/12
摘要： A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R 5 is an optionally substituted C 5-20 aryl or C 4-20 alkyl group; L' is a single bond, -O- or -C(=O)-; A is selected from the group consisting of: formulae (i) (ii) (iii) wherein X and Y are selected from the group consisiting of: O and CR 3 ; S and CR 3 ; NH and CR 3 ; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formulae (i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix) B is selected from the group consisting of: formulae (A) (B) where R P6 is selected from fluoro and chloro; and R 2 is either: (i) -CO 2 H; (ii) -CONH 2 ; (iii) -CH 2 -OH; or (iv) tetrazol-5-yl.
摘要翻译：式（III）化合物或其盐，溶剂合物和化学保护形式，其中：R 5是任选取代的C 5-20-20芳基或C _{4-20 烷基; L'是单键，-O-或-C（= O） - ; A选自由式（ⅰ）（ⅱ）（ⅲ）组成的组：其中X和Y选自：O和CR 3; S和CR 3; NH和CR 3; NH和N; O和N; S和N; N和S; 和N和O，并且其中虚线表示适当位置的双键，并且其中Q为N或CH; D选自：式（i）（ii）（iii）（iv）（v）（vi）（vii）（viii）（ix）B选自：式（A）（B）其中 R 6 P 6选自氟和氯; 和R 2是：（i）-CO 2 H; （ii）-CONH 2; （iii）-CH 2 -OH; 或（iv）四唑-5-基。}

7. 发明申请

WO2007017687A3 EP2 RECEPTOR AGONISTS 审中-公开
标题翻译： EP2受体激素
公开(公告)号：WO2007017687A3
公开(公告)日：2007-05-31
申请号：PCT/GB2006002979
申请日：2006-08-09
申请人： ASTERAND UK LTD , OXFORD ALEXANDER WILLIAM , DAVIS RICHARD JON , COLEMAN ROBERT ALEXANDER , CLARK KENNETH LYLE , CLARK DAVID EDWARD , HARRIS NEIL VICTOR , FENTON GARRY , HYND GEORGE , STUTTLE KEITH ALFRED JAMES , SUTTON JONATHAN MARK , ASHTON MARK RICHARD , BOYD EDWARD ANDREW , BRUNTON SHIRLEY ANN
发明人： OXFORD ALEXANDER WILLIAM , DAVIS RICHARD JON , COLEMAN ROBERT ALEXANDER , CLARK KENNETH LYLE , CLARK DAVID EDWARD , HARRIS NEIL VICTOR , FENTON GARRY , HYND GEORGE , STUTTLE KEITH ALFRED JAMES , SUTTON JONATHAN MARK , ASHTON MARK RICHARD , BOYD EDWARD ANDREW , BRUNTON SHIRLEY ANN
IPC分类号： C07D307/42 , A61K31/4418 , A61P11/06 , C07C233/80 , C07C257/18 , C07D213/70 , C07D263/56 , C07D307/54 , C07D307/91 , C07D405/12
CPC分类号： C07C233/81 , C07C257/18 , C07D213/70 , C07D263/57 , C07D307/42 , C07D307/54 , C07D307/68 , C07D307/91 , C07D405/12
摘要： A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R 5 is an optionally substituted C 5-20 aryl or C 4-20 alkyl group; L' is a single bond, -O- or -C(=O)-; A is selected from the group consisting of: formulae (i) (ii) (iii) wherein X and Y are selected from the group consisiting of: O and CR 3 ; S and CR 3 ; NH and CR 3 ; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formulae (i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix) B is selected from the group consisting of: formulae (A) (B) where R P6 is selected from fluoro and chloro; and R 2 is either: (i) -CO 2 H; (ii) -CONH 2 ; (iii) -CH 2 -OH; or (iv) tetrazol-5-yl.
摘要翻译：式（III）化合物或其盐，溶剂合物和化学保护形式，其中：R 5是任选取代的C 5-20-20芳基或C _{4-20 烷基; L'是单键，-O-或-C（= O） - ; A选自由式（ⅰ）（ⅱ）（ⅲ）组成的组：其中X和Y选自：O和CR 3; S和CR 3; NH和CR 3; NH和N; O和N; S和N; N和S; 和N和O，并且其中虚线表示适当位置的双键，并且其中Q为N或CH; D选自：式（i）（ii）（iii）（iv）（v）（vi）（vii）（viii）（ix）B选自：式（A）（B）其中 R 6 P 6选自氟和氯; 和R 2是：（i）-CO 2 H; （ii）-CONH 2; （iii）-CH 2 -OH; 或（iv）四唑-5-基。}

8. 发明申请

WO2005080367A1 EP2 RECEPTOR AGONISTS 审中-公开
标题翻译： EP2受体激素
公开(公告)号：WO2005080367A1
公开(公告)日：2005-09-01
申请号：PCT/GB2005/000462
申请日：2005-02-11
申请人： PHARMAGENE LABORATORIES LIMITED , OXFORD, Alexander, William , DAVIS, Richard, Jon , COLEMAN, Robert, Alexander , CLARK, Kenneth, Lyle , CLARK, David, Edward , HARRIS, Neil, Victor , FENTON, Garry , HYND, George , STUTTLE, Keith, Alfred, James , SUTTON, Jonathan, Mark , ASHTON, Mark, Richard , BOYD, Edward, Andrew , BRUNTON, Shirley, Ann
发明人： OXFORD, Alexander, William , DAVIS, Richard, Jon , COLEMAN, Robert, Alexander , CLARK, Kenneth, Lyle , CLARK, David, Edward , HARRIS, Neil, Victor , FENTON, Garry , HYND, George , STUTTLE, Keith, Alfred, James , SUTTON, Jonathan, Mark , ASHTON, Mark, Richard , BOYD, Edward, Andrew , BRUNTON, Shirley, Ann
IPC分类号： C07D307/68
CPC分类号： C07D213/81 , C07C233/75 , C07C233/81 , C07C235/84 , C07D233/90 , C07D257/04 , C07D277/24 , C07D277/26 , C07D277/56 , C07D307/46 , C07D307/68 , C07D307/91 , C07D333/38 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12
摘要： A compound of Formula (I) or a salt, solvate and chemically protected form thereof, wherein: R 5 is an optionally substituted C 5-20 aryl or C 4-20 alkyl group; A is selected from the group consisting of Formulae (Ai), (Aii), (Aiii) D is selected from Formulae (Di), (Dii), (Diii), (Div), (Dv) B is selected from the group consisting of Formulae (Bi), (Bii), (Biii), (Biv) (Bv).
摘要翻译：式（I）化合物或其盐，溶剂化物和化学保护形式，其中：R 5为任选取代的C 5-20芳基或C 4-20烷基; A选自式（Ai），（Aii），（Aiii）D选自式（Di），（Dii），（Diii），（Div），（Dv）B选自组由式（Bi），（Bii），（Biii），（Biv）（Bv）组成。

9. 发明申请

WO2005037812A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS 审中-公开
标题翻译： FURAN衍生物作为EP4受体拮抗剂
公开(公告)号：WO2005037812A1
公开(公告)日：2005-04-28
申请号：PCT/GB2004/004392
申请日：2004-10-15
申请人： PHARMAGENE LABORATORIES LIMITED , CLARK, David, Edward , HARRIS, Neil, Victor , FENTON, Garry , HYND, George , STUTTLE, Keith, Alfred, James , SUTTON, Jonathan, Mark , OXFORD, Alexander, William , DAVIS, Richard, Jon , COLEMAN, Robert, Alexander , CLARK, Kenneth, Lyle
发明人： CLARK, David, Edward , HARRIS, Neil, Victor , FENTON, Garry , HYND, George , STUTTLE, Keith, Alfred, James , SUTTON, Jonathan, Mark , OXFORD, Alexander, William , DAVIS, Richard, Jon , COLEMAN, Robert, Alexander , CLARK, Kenneth, Lyle
IPC分类号： C07D307/68
CPC分类号： C07D307/68
摘要： A compound of formula: (I); or a salt, solvate and chemically protected form thereof, wherein one of R 2 and R 5 is: (i) H or an optionally substituted C 1-4 alkyl group; or (ii)an optionally substituted C 5-7 aryl; and the other of R 2 and R 5 is the other group; m and n can be 0 or 1, and m + n = 1 or 2 R N is H or optionally substituted C 1-4 alkyl R 3 is either: (i) carboxy; (ii) a group of formula: (II); (iii) a group of formula: (III); wherein R is optionally substituted C 1-7 alkyl, C 5-20 aryl, or NR N3 R N4 , where R N3 and R N4 are independently selected from optionally substituted C 1-4 alkyl; or (iv) tetrazol-5-yl.
摘要翻译：式（I）化合物：或其盐，溶剂合物和化学保护形式，其中R 2和R 5之一为：（i）H或任选取代的C 1-4烷基; 或（ii）任选取代的C 5-7芳基; R 2和R 5中的另一个是另一个基团; m和n可以是0或1，m + n = 1或2 R N是H或任选取代的C 1-4烷基R 3是：（i）羧基; （ii）一组式（II）; （iii）式（III）的一组：其中R是任选取代的C 1-7烷基，C 5-20芳基或NR N 3 R 4，其中R N 3和R N 4独立地选自任选取代的C 1-4烷基; 或（iv）四唑-5-基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式